SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on December 3, 2018, covering events occurring on November 29, 2018. The filing reports the appointment of a new director to the Company's Board of Directors and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to executive compensation: Dr. Gil Price was awarded stock options to purchase 112,878 shares of common stock under the Company's 2013 Stock Option Plan. He is also eligible for a pro-rated portion of the 2018 annual retainer and committee fees for non-employee directors.
Material Changes
The primary material change reported is the expansion of the Board of Directors. Dr. Gil Price, M.D., was appointed effective November 29, 2018, to serve until the 2019 annual meeting of stockholders. He has been assigned to the Compensation Committee and the Nominating and Corporate Governance Committee.
Outlook, Risks, and Management Commentary
Management highlighted Dr. Price's extensive background in drug development, pharmacovigilance, and clinical operations, including prior roles at ProPharma Group, Drug Safety Solutions, MedImmune, and Glaxo Inc., as well as board service at Sarepta Therapeutics. The filing references a press release issued on December 3, 2018, for further details. No specific risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Confirm the exact vesting schedule and exercise price for the 112,878 stock options granted to Dr. Price.
- Review the Company's 2018 annual proxy statement for details on the non-employee director compensation program.
- Verify the impact of the new board member on the Company's strategic direction regarding drug safety and development.